Publications by authors named "L Pena Quintana"
The document provides a comprehensive overview of the diagnosis, monitoring, and treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) with renal involvement, focusing on granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). It outlines the definitions, clinical presentation, histopathological classification, monitoring strategies, induction and maintenance treatments, as well as special considerations for relapsing, refractory, and frail patients with renal AAV. The document was prepared by the Catalan Group for the Study of Glomerular Diseases (GLOMCAT), which comprises nephrologists with extensive experience in the diagnosis and treatment of AAV patients.
View Article and Find Full Text PDFArticle Synopsis
- * Recent studies indicate that a specific TE-derived gene, POGK, functions as a tumor suppressor in triple-negative breast cancer (TNBC) by interfering with the expression of ribosomal genes.
- * POGK’s deactivation occurs through isoform switching in patients with clinical TNBC, highlighting its importance in regulating tumor development.
Background: Antipsychotic medications (AP) are inappropriately prescribed to young people. The goal of this pragmatic trial was to test a four-component approach to improved targeting of antipsychotic prescribing to people aged ≥3 and <18 years.
Methods: Clinicians in four health systems were cluster randomized by the number of previous AP orders and service line - specialty mental health and all others.
Article Synopsis
- A retrospective study of 183 adult patients treated with rituximab for podocytopathies showed that 82% achieved complete or partial remission within 6 months.
- *Long-term follow-up revealed that 55% of initial responders maintained relapse-free survival over three years, with improved outcomes linked to maintenance therapy.
- *Patients on maintenance therapy experienced significantly fewer relapses per year and maintained stable kidney function compared to non-responders.
Article Synopsis
- Previous research has shown that both (R,S)-ketamine and its metabolite (2S,6S)-HNK can reduce learned fear in mice when administered before experiencing stress.
- A study involved injecting mice with these compounds and then assessing neural activity related to fear after a fear conditioning task.
- The findings suggest that both drugs affect different neural pathways associated with fear and could lead to new methods for treating fear-related disorders by targeting specific brain areas.